CSBR Champions Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CSBR

Price (delayed)

$5.76

Market cap

$79.99M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.17

Enterprise value

$77.76M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 16

Champions Oncology is a data-driven research organization that leverages an oncology research center of excellence to develop transformative technology and accelerate oncology research and development. This technology ranges from computational-based ...

Highlights
The debt fell by 24% YoY and by 7% QoQ
Champions Oncology's equity has decreased by 22% YoY but it has increased by 2.7% QoQ
CSBR's quick ratio is down by 3.1% year-on-year but it is up by 2.2% since the previous quarter
The company's EPS has shrunk by 194% QoQ and by 136% YoY
The net income has plunged by 192% from the previous quarter and by 136% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.championsoncology.com
Peers: CRL EXEL CLDX

Key stats

What are the main financial stats of CSBR

CSBR stock price

How has the Champions Oncology stock price performed over time
Intraday
1.23%
1 week
-1.54%
1 month
-2.21%
1 year
-9.72%
YTD
-16.64%
QTD
0.17%

Financial performance

How have Champions Oncology's revenue and profit performed over time
Revenue
$57.94M
Gross profit
$26.58M
Operating income
-$2.63M
Net income
-$2.28M
Gross margin
45.9%
Net margin
-3.9%
The net income has plunged by 192% from the previous quarter and by 136% YoY
The net margin has shrunk by 191% QoQ and by 135% YoY
The operating margin has plunged by 142% YoY
The company's operating income has shrunk by 142% YoY

Price vs fundamentals

How does CSBR's price correlate with its fundamentals

Growth

What is Champions Oncology's growth rate over time

Valuation

What is Champions Oncology stock price valuation
CSBR P/E details
P/E
N/A
P/B
18.68
P/S
1.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.34
The company's EPS has shrunk by 194% QoQ and by 136% YoY
CSBR's P/B is 74% below its 5-year quarterly average of 71.5 and 24% below its last 4 quarters average of 24.3
Champions Oncology's equity has decreased by 22% YoY but it has increased by 2.7% QoQ
The price to sales (P/S) is 24% lower than the 5-year quarterly average of 1.8 and 20% lower than the last 4 quarters average of 1.7

Efficiency

How efficient is Champions Oncology business performance
The company's return on sales has shrunk by 198% QoQ and by 137% YoY
CSBR's ROE has shrunk by 198% QoQ and by 109% YoY
The ROA has plunged by 193% from the previous quarter and by 131% YoY
The company's return on invested capital has shrunk by 191% YoY

Dividends

What is CSBR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CSBR.

Financial health

How did Champions Oncology financials performed over time
The total assets is 18% greater than the total liabilities
The total liabilities has contracted by 7% from the previous quarter and by 4.3% YoY
The total assets has declined by 7% year-on-year and by 6% since the previous quarter
The debt is 14% higher than the equity
The debt fell by 24% YoY and by 7% QoQ
Champions Oncology's equity has decreased by 22% YoY but it has increased by 2.7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.